leisure time -WSS

leisure time

author：leisure time 2025-09-29 01:09:37 - browse：7

Adam's take main illustration — Molly Ferguson/STAT

For two days starting on Sunday, Moonlake Immunotherapeutics happily crunched numbers and shared results from a mid-stage clinical trial that depicted its experimental antibody in the most flattering terms possible.

The drug, called sonelokimab, was “changing the game” for the treatment of a debilitating skin condition called hidradenitis suppurativa, or HS, said Moonlake CEO Jorge Santos da Silva, on a call for investors and analysts. The drug’s benefit for patients placed it “at the top of the heap,” he added.

For other, equally important data from the same study that did not fit Moonlake’s home-run narrative, the company took a DIY approach. Curious about how sonelokimab performed against a treatment that’s already approved for HS? Pull out a calculator and do the math yourself. How badly did a higher dose of the drug underperform a lower dose? Take a guess.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Cancer drug shortages should be causing more outrage
Next article： Friends ask where James Watson's attitudes about race came from

explore

WSS

Patients' immediate access to test results puts radiologists in a bind

Q&A: Figuring out how songbirds sing may lead to better understanding of how humans learn

Pharma patents targeted by Biden in move to slash drug prices

Naloxone nonprofit donates 200,000 doses after FDA approval

Leukemia patients are helped by Syndax's new type of therapy

In same hospitals, Black patients receive fewer opioids than white patients

leisure time

leisure time

knowledge

The high cost of giving birth even with insurance

Emergent cuts jobs, executive role in business shake

Drug repurposing or repositioning? The language matters

Sanofi says it has 12 blockbusters on the way. Will investors believe it?

Tori Bowie and the unacceptable rates of Black maternal death

FDA panel issues narrow recommendation for Covid vaccine booster doses

Dobbs anniversary: the lost opportunity of abortion as health care

After sickle

Duchenne breakthrough therapy leaves behind pioneering families

Man killed during FBI raid in connection with threats against Biden, other officials

hotspot

Police still searching for prisoner who escaped from NYC hospital

For Cytokinetics, FDA rejection of heart drug would help, not hinder

Roche to buy Carmot Therapeutics, developer of obesity drugs

Pregnancy discrimination could be enabled by AI

What PEPFAR has meant on the ground in Ukraine

Wayne Brady comes out as pansexual: 'Free to love whomever I want'

hotspot

explore

focus

focus